131 related articles for article (PubMed ID: 38492903)
1. Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
Colombel JF; Hisamatsu T; Atreya R; Bresso F; Thin L; Panaccione R; Parra RS; Ford S; Remple VP; Lacerda AP; Anyanwu SI; Mallick M; Garrison A; Regueiro M
Clin Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38492903
[TBL] [Abstract][Full Text] [Related]
2. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Peyrin-Biroulet L; Panaccione R; Louis E; Atreya R; Rubin DT; Lindsay JO; Siffledeen J; Lukin DJ; Wright J; Watanabe K; Ford S; Remple VP; Lacerda AP; Dubcenco E; Garrison A; Zhou Q; Berg S; Anyanwu SI; Schreiber S
Clin Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38492904
[TBL] [Abstract][Full Text] [Related]
3. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
Loftus EV; Panés J; Lacerda AP; Peyrin-Biroulet L; D'Haens G; Panaccione R; Reinisch W; Louis E; Chen M; Nakase H; Begun J; Boland BS; Phillips C; Mohamed MF; Liu J; Geng Z; Feng T; Dubcenco E; Colombel JF
N Engl J Med; 2023 May; 388(21):1966-1980. PubMed ID: 37224198
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
Vermeire S; Danese S; Zhou W; Ilo D; Klaff J; Levy G; Yao X; Chen S; Sanchez Gonzalez Y; Hébuterne X; Lindsay JO; Higgins PDR; Cao Q; Nakase H; Colombel JF; Loftus EV; Panaccione R
Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):976-989. PubMed ID: 37683686
[TBL] [Abstract][Full Text] [Related]
5. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
[TBL] [Abstract][Full Text] [Related]
6. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
Loftus EV; Colombel JF; Takeuchi K; Gao X; Panaccione R; Danese S; Dubinsky M; Schreiber S; Ilo D; Finney-Hayward T; Zhou W; Phillips C; Gonzalez YS; Shu L; Yao X; Zhou Q; Vermeire S
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2347-2358.e6. PubMed ID: 36464141
[TBL] [Abstract][Full Text] [Related]
7. Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
Colombel JF; Schreiber S; D'Haens G; Rizzo J; Kligys K; Griffith J; Zambrano J; Zhou Q; Zhang Y; Kalabic J; Rieder F; Dubinsky MC; Panaccione R
J Crohns Colitis; 2024 Jun; 18(6):818-827. PubMed ID: 38069472
[TBL] [Abstract][Full Text] [Related]
8. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
[TBL] [Abstract][Full Text] [Related]
10. Impact of upadacitinib induction and maintenance therapy on health-related quality of life, fatigue, and work productivity in patients with moderately-to-severely active Crohn's disease.
Ghosh S; Feagan BG; Parra RS; Lopes S; Steinlauf A; Kakuta Y; Joshi N; Lee WJ; Lacerda AP; Zhou Q; Xuan S; Kligys K; Shukla N; Louis E
J Crohns Colitis; 2024 Jun; ():. PubMed ID: 38835235
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
[TBL] [Abstract][Full Text] [Related]
12. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
[TBL] [Abstract][Full Text] [Related]
13. Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data.
Danese S; Tran J; D'Haens G; Rubin DT; Aoyama N; Zhou W; Ilo D; Yao X; Sanchez Gonzalez Y; Panaccione R
Inflamm Bowel Dis; 2023 Nov; 29(11):1723-1729. PubMed ID: 36790041
[TBL] [Abstract][Full Text] [Related]
14. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; Ferrante M
Lancet; 2022 May; 399(10340):2015-2030. PubMed ID: 35644154
[TBL] [Abstract][Full Text] [Related]
15. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
[TBL] [Abstract][Full Text] [Related]
16. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
Colombel JF; Sands BE; Gasink C; Yeager B; Adedokun OJ; Izanec J; Ma T; Gao LL; Lee SD; Targan SR; Ghosh S; Hanauer SB; Sandborn WJ
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):144-153.e2. PubMed ID: 37391056
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease.
Peyrin-Biroulet L; Louis E; Loftus EV; Lacerda A; Zhou Q; Sanchez Gonzalez Y; Ghosh S
Adv Ther; 2021 May; 38(5):2339-2352. PubMed ID: 33755884
[TBL] [Abstract][Full Text] [Related]
19. Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease.
Sandborn WJ; Lewis JD; Panes J; Loftus EV; D'Haens G; Yu Z; Huang B; Lacerda AP; Pangan AL; Feagan BG
J Crohns Colitis; 2022 Mar; 16(3):444-451. PubMed ID: 34546360
[TBL] [Abstract][Full Text] [Related]
20. Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.
Feagan B; Sandborn WJ; Rutgeerts P; Levesque BG; Khanna R; Huang B; Zhou Q; Maa JF; Wallace K; Lacerda A; Thakkar RB; Robinson AM
Inflamm Bowel Dis; 2018 Apr; 24(5):932-942. PubMed ID: 29668919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
